Iovance Biotherapeutics (HAM:2LB) Institutional Ownership: 29.86% (As of Jul. 07, 2026)


HAM:2LB Iovance Biotherapeutics Inc HAM:2LB
44 GF Score
Price €3.78
GF Value €17.09
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics Institutional Ownership?

Iovance Biotherapeutics HAM:2LB +2.44% 44 Institutional Ownership is 29.86% as of Jul. 07, 2026. GuruFocus rates HAM:2LB with a GF Score™ of 44/100 and a GF Value™ of €17.09 (Possible Value Trap). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Iovance Biotherapeutics's institutional ownership is 29.86%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Iovance Biotherapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Iovance Biotherapeutics's Float Percentage Of Total Shares Outstanding is 93.41%.

Iovance Biotherapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Iovance Biotherapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iovance Biotherapeutics Institutional Ownership Chart

Iovance Biotherapeutics Historical Data

The historical data trend for Iovance Biotherapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 25.78 25.12 24.93 26.95 26.96 27.31 27.09 27.04 27.61 29.66
HAM:2LB
44GF Score
Iovance Biotherapeutics Inc HAM:2LB
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iovance Biotherapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 29.86% mean?
Iovance Biotherapeutics (HAM:2LB) has a Institutional Ownership of 29.86% as of Jul. 07, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Iovance Biotherapeutics and its competitors.
Is Iovance Biotherapeutics' Institutional Ownership too high?
Iovance Biotherapeutics' current Institutional Ownership is 29.86%. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Institutional Ownership compare to SNDX and GLUE?
Iovance Biotherapeutics' Institutional Ownership of 29.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Iovance Biotherapeutics and its competitors. Iovance Biotherapeutics's current Institutional Ownership is 29.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (HAM:2LB) is currently considered Possible Value Trap. The stock's GF Value™ is €17.09, compared to a current price of €3.78 — trading 77.9% below its estimated fair value. The current Institutional Ownership is 29.86%. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Iovance Biotherapeutics (HAM:2LB), the current Institutional Ownership is 29.86% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iovance Biotherapeutics (HAM:2LB) Overvalued in 2026?

Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued. The current stock price of €3.78 is trading 77.9% below its estimated GF Value™ of €17.09. GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.

Key valuation signals for HAM:2LB:

  • Institutional Ownership: 29.86%
  • GF Value™: €17.09 vs. price of €3.78 (77.9% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the HAM:2LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score

Get the complete analysis for HAM:2LB

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.78
Price
€17.09
GF Value